3种不同α受体阻滞剂治疗良性小体积前列腺增生伴下尿路症状患者临床比较  

Clinical comparison of different alpha-blockers in the treatment of benign small volume prostatic hyperplasia with lower urinary tract symptoms

作　　者：徐凌 冯建伟[1] 郎金田[1] 乔弘宇 崔刚[1] XU Ling;FENG Jian-wei;LANG Jin-tian;QIAO Hong-yu;CUI Gang(Department of Urology Surgery,Beijing Daxing District People s Hospital,Beijing 102600,China)

机构地区：[1]北京市大兴区人民医院泌尿外科,北京102600

出　　处：《川北医学院学报》2023年第6期810-813,817,共5页Journal of North Sichuan Medical College

摘　　要：目的:比较3种不同α受体阻滞剂治疗良性小体积前列腺增生(BPH)伴下尿路症状(LUTS)患者的疗效、经济性与安全性。方法:选取108例良性小体积前列腺增生伴下尿路症状患者作为研究对象,根据治疗药物不同分为特拉唑嗪组(n=54)、多沙唑嗪组(n=30)及坦索罗辛组(n=24),疗程结束后评价疗效、药物经济性及安全性。结果:治疗后,3组Q_(max)、Q ave、TPV、PVR、梗阻评分、刺激评分、IPSS总评分均较治疗前改善(P<0.05),但组间Q_(max)、Q_(ave)、TPV、PVR、梗阻评分、刺激评分、IPSS总评分、SBP、DBP比较,差异均无统计学意义(P>0.05);各组症状改善率比较,差异无统计学意义(P>0.05);各组成本/效果比较:多沙唑嗪组>坦索罗辛组>特拉唑嗪组(P<0.05);各组不良反应发生率比较:多沙唑嗪组<坦索罗辛组<特拉唑嗪组(P<0.05)。结论:3种α受体阻滞剂疗效基本相同,但从药物经济学角度,特拉唑嗪最优,安全性角度多沙唑嗪最优,可根据患者需求进行选择。Objective:To compare the efficacy,economy and safety of three different α-blockers in the treatment of benign small volume prostatic hyperplasia(BPH)with lower urinary tract symptoms(LUTS).Methods:108 cases of benign small volume prostatic hyperplasia with lower urinary tract symptoms were selected as the reseatch subjects.According to different drugs,they were divided into three groups:terazosin group(n=54),doxazosin group(n=30)and tamsulosin group(n=24).After the treatment,the efficacy,pharmacoeconomics and safety were evaluated.Results:After treatment,Q_(max),Q_(ave),TPV,PVR,obstruction score,stimulation score and IPSS total score were improved compared with those before treatment(P<0.05).There were no significant differences in Q_(max),Q_(ave) TPV,PVR,obstruction score,stimulation score,IPSS total score,SBP and DBP among the three groups after treatment(P>0.05).There was no statistically significant difference in symptom improvement rates among groups(P>0.05).Cost/effect comparison of each group:doxazosin group>tamsulosin group>terazosin group(P<0.05),adverse reaction rate comparison of each group:doxazosin group<tamsulosin group<terazosin group(P<0.05).Conclusion:The efficacy of the threeα-blockers is basically the same,but from the perspective of pharmacoeconomics,Terazosin is the best,and doxazosin is the best from the perspective of safety,which can be selected according to patient needs.

关 键 词：特拉唑嗪 多沙唑嗪 坦索罗辛 前列腺增生 下尿路症状 

分 类 号：R699[医药卫生—泌尿科学]